CERT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4595108	1.00	3/20
SCHEMBL7765658	0.67	3/20
SCHEMBL7765661	0.67	3/20
SCHEMBL8342096	0.67	3/20
SCHEMBL8383184	0.67	3/20
SCHEMBL6570067	0.66	3/20
SCHEMBL7769010	0.66	3/20
SCHEMBL7769012	0.66	3/20
SCHEMBL8338663	0.66	3/20
SCHEMBL6571640	0.65	3/20
SCHEMBL7773484	0.65	3/20
SCHEMBL7773486	0.65	3/20
SCHEMBL8341808	0.65	3/20
SCHEMBL9763082	0.63	3/20
SCHEMBL8335749	0.62	3/20
SCHEMBL4139305	0.61	3/20
SCHEMBL4139311	0.61	3/20
SCHEMBL4183115	0.61	3/20
SCHEMBL5599045	0.61	3/20
SCHEMBL9472620	0.61	3/20

Clinical trials — most relevant to CERT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.	PHASE4	COMPLETED
Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis	PHASE4	COMPLETED
Hereditary Sensory Neuropathy Serine Trial	PHASE2	UNKNOWN
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo	PHASE2	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Sphingo-lipotoxicity and Trans-differentiation of Adipose Tissue in Obesity (SFINGOTRANS)	nan	COMPLETED
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure	nan	COMPLETED
The Heart-Mind Connection: Evaluating the Association Between Ceramides and Cognitive Decline in Coronary Artery Disease	nan	COMPLETED
Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial	nan	COMPLETED
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales	nan	RECRUITING
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease	nan	COMPLETED
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention	nan	UNKNOWN
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome	nan	COMPLETED
Effect of Plasma Ceramides on Peripheral Vascular Function	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma	nan	RECRUITING
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Precision Medicine for Sng/Pain Control	nan	COMPLETED
Evaluation of Serum Ceramides C16, C24, and Sphingosine-1-Phosphate (S1P) in Patients With Acne Vulgaris	nan	NOT_YET_RECRUITING
Genes Involved in Lipid Disorders	nan	COMPLETED
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children	nan	NOT_YET_RECRUITING
Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders	nan	UNKNOWN
Genetic and Metabolic Disease in Children	nan	RECRUITING
Genomic Dissection of a QTL Affecting the Lipid Profile	nan	WITHDRAWN
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV	nan	NOT_YET_RECRUITING
Metabolic Optimization Through Diet/Lifestyle Improvements For Youth	nan	UNKNOWN
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CERT1 binder may also engage these)

Protein	Name	Similarity
Q5R6M6	—	1.000	Q5R6M6 →
Q6NRZ4	—	1.000	Q6NRZ4 →
Q9EQG9	—	1.000	Q9EQG9 →
Q6P3Q6	—	1.000	Q6P3Q6 →
Q6VVX2	—	0.999	Q6VVX2 →
Q9GKI7	—	0.998	Q9GKI7 →
Q5M7Y0	—	0.994	Q5M7Y0 →
Q9BXB4	—	0.983	Q9BXB4 →
Q8BWW9	—	0.979	Q8BWW9 →
Q8CI95	—	0.978	Q8CI95 →
PKN2	Serine/threonine-protein kinase N2	0.977	landscape →
A7MBL8	—	0.977	A7MBL8 →
Q07139	—	0.974	Q07139 →
Q9ESL4	—	0.974	Q9ESL4 →
Q9H8V3	—	0.974	Q9H8V3 →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.973	landscape →
Q9UKG1	—	0.972	Q9UKG1 →
Q8K1Y2	—	0.970	Q8K1Y2 →
B4F779	—	0.970	B4F779 →
Q9UPW5	—	0.970	Q9UPW5 →
Q6QD73	—	0.970	Q6QD73 →
Q5RDV5	—	0.970	Q5RDV5 →
Q641K1	—	0.969	Q641K1 →
Q8N6S4	—	0.969	Q8N6S4 →
PRKD1	Serine/threonine-protein kinase D1	0.969	landscape →
Q8K3H0	—	0.969	Q8K3H0 →
SNX9	Sorting nexin-9	0.968	landscape →
B9EJ86	—	0.968	B9EJ86 →
MAP3K5	Mitogen-activated protein kinase kinase kinase 5	0.968	landscape →
P28028	—	0.968	P28028 →